Company Overview of Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc., a biotechnology company, engages in developing cancer treatments. It offers ODSH, a low anticoagulant heparin derivative that reduces the incidence, severity, and duration of reduction of platelet counts caused by chemotherapy. The company also provides Disulfiram-Copper Chelate that includes non-overlapping cancer stem cell killing mechanisms of actions, including proteasome inhibition, induction of reactive oxygen species, and strong inhibition of ALDH and the NF Kappa B pathways for metastatic breast cancer, pancreatic cancer, and glioblastoma. Cantex Pharmaceuticals, Inc. was formerly known as PARINGENIX INC. The company was incorporated in 2002 and is based...
1792 Bell Tower Lane
Weston, FL 33326
Founded in 2002
Key Executives for Cantex Pharmaceuticals, Inc.
Chairman and Chief Executive Officer
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.
Cantex Pharmaceuticals, Inc. Key Developments
Cantex Pharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 through Oct-21-2015
Sep 3 15
Cantex Pharmaceuticals, Inc. Presents at 14th Annual BIO Investor Forum, Oct-20-2015 through Oct-21-2015. Venue: Parc 55 Hotel, San Francisco, California, United States. Presentation Date & Speakers: Oct-20-2015, Stephen G. Marcus, President and Director. Oct-21-2015.
Cantex Pharmaceuticals Announces Management Appointments
Aug 13 15
Cantex Pharmaceuticals, Inc. announced key additions to its senior management team that bring strategic experience in finance and clinical operations as the Company advances its corporate and development strategies. New members of the executive management team include Juan F. Rodriguez, Chief Financial Officer, and Karen Ivester, RN, MA, PMP, Vice President of Clinical Operations. Juan Rodriguez brings more than 20 years of financial and business leadership experience to Cantex, the majority of which has been in the life sciences field. Most recently, Mr. Rodriguez served as Chief Financial Officer at OPKO Health, Inc. and has, since 2007, served as Chairman of the Advisory Board of Cognitec Systems GmbH, a German software developer. From 1995 to 2007, prior to its acquisition by Abbott Laboratories, Mr. Rodriguez was with Kos Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company engaged in the development and commercialization of proprietary prescription products. Karen Ivester has 28 years' experience managing clinical trials, including 14 years' direct experience in oncology therapeutics. Prior to Cantex, Ms. Ivester held the positions of Head Early Phase Oncology, Solid Tumor Division for Quintiles; Director, Global Hematology/Oncology Group at Pharmaceutical Product Development (PPD-CRO); Senior Portfolio Director, Account and Partnership Management at PAREXEL; and Senior Project Manager at Quintiles Transnational.
Cantex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:40 AM
Apr 6 15
Cantex Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|